Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cipralisant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cipralisant SCHEMBL7069808 | 1.00 | HRH3 (0.57) | HRH3 | |
| Cipralisant SCHEMBL8395048 | 1.00 | HRH3 (0.57) | HRH3 | |
| SCHEMBL8397428 | 0.81 | HRH3 (0.37) | HRH3 | |
| SCHEMBL8395186 | 0.80 | HRH3 (0.36) | HRH3 | |
| SCHEMBL8397521 | 0.79 | HRH3 (0.36) | HRH3 | |
| SCHEMBL8397507 | 0.74 | HRH3 (0.33) | HRH3 | |
| Cipralisant SCHEMBL1649825 | 0.73 | HRH3 (1.00) | HRH3 | |
| SCHEMBL8314636 | 0.73 | HRH3 (0.30) | HRH3 | |
| SCHEMBL6136538 | 0.70 | — | — | |
| SCHEMBL18998463 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4251148-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Richter Gedeon Nyrt. (HU) | 2023-10-04 | — | — | EP | claimed |
| WO-2022113008-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | RICHTER GEDEON NYRT. (HU) | 2022-06-02 | — | — | WO | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-3369419-B1 | COMPOSITION FOR TREATING DIABETES | KATO YASUMASA (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023225492-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007116092-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2004066960-A2 | COMBINATION OF H1, H3 AND H4 RECEPTOR ANTAGONISTS FOR TREATMENT OF ALLERGIC AND NON-ALLERGIC PULMONARY INFLAMMATION, CONGESTION AND ALLERGIC RHINITIS | SCHERING CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | GLIATECH, INC. | 2003-04-10 | — | — | US | disclosed |
| US-6008240-A | AN ANTAGONIST OF HISTAMINE H3 RECEPTORS; FOR TREATING ALLERGY, INFLAMMATION, CARDIOVASCULAR DISEASE (HYPER OR HYPOTENSION), GASTROINTESTINAL DISORDERS, CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS | GLIATECH, INC. (US) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | HRH3 2876/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | HRH3 672/4885 |
| US-20070244177-A1 | ENZYME INHIBITORS | ACHE, BACE1, MAOA | HRH3 586/4885 |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS2, GLS, GLUL | HRH3 738/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | HRH3 3968/4885 |
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | HRH3, HRH4, HRH2 | HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.